Gilead Sciences stock heads into the open after a 0.52% dip
Published on 09/21/2026 at 06:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock closed at USD 150.11 on Nasdaq on September 18, 2026, down 0.52% from the prior session. The move left the shares close to the upper band of their recent 52-week trading range and broadly in line with the performance of large-cap biopharma peers.
September 18, 2026 in numbers
Gilead Sciences Inc. (ISIN US3755581036, Nasdaq: GILD) ended the September 18, 2026 session at USD 150.11 on Nasdaq, a decline of 0.78 dollars or 0.52%, based on exchange data as of 16:00 Eastern Time. Per Nasdaq data reproduced by MarketBeat, the shares traded between approximately USD 149 and USD 151 during the regular session, with a closing volume of about 3,600,000 shares, underscoring solid liquidity for the day.
According to price information summarized by a major US stock portal on September 18, 2026, Gilead Sciences shares finished the regular session at USD 150.11 before edging higher in after-hours trading that evening. Per MarketBeat data, the September 18, 2026 close at USD 150.11 represented a modest pullback within a broader uptrend that has carried the stock higher over recent months, leaving it nearer the top portion of its published 52-week range.
Outlook for today, September 21, 2026
Company-specific events for Gilead Sciences today are not highlighted in major public earnings calendars, but broader macro and sector signals still matter for the shares. The economic calendar compiled by Finostat points to speeches by members of the Federal Reserve and the European Central Bank on September 21, 2026, events that can influence rate expectations and risk appetite across equity markets, including defensive healthcare and biopharma names such as Gilead Sciences. With the last close placing the stock near the higher end of its recent trading band and daily volume around 3.6 million shares on September 18, 2026, investors today are likely to weigh sector news and macro commentary as they position Gilead Sciences stock ahead of upcoming corporate catalysts.
